… clinical development of SAR405838 and other HDM2 antagonists. We … , including a mutant
p53 activating drug like APR-246, MEK or … Safety, pharmacokinetics, pharmacodynamics and …

… small molecular inhibitors including SAR405838 and HDM201. … required drug discontinuation,
and 12 required drug dose … Novel drugs designed to simultaneously inhibit both MDM2 …

… safety studies, where it demonstrated a profile that supported its progression to the clinic. …
incorporates various drug discovery principles and technologies to optimize novel compounds, …

… including overexpression of its key negative regulator HDM2, the human homologue of
mouse … regulator MDM2 has recently been explored as a novel approach to cancer therapy. …

… by the US Food and Drug Administration (FDA). … first-in-human phase I trial in 68 patients
with solid malignancies evaluated once-per-day and once-per-week schedules of SAR405838…

… antagonists approved in clinical to treat prostate cancer [16]. Enzalutamide is the first
second-generation AR antagonist … breakthrough for both functional study and drug design. Along …

… In contrast, DDLPS can respond to chemotherapy drugs and drug … and genomic characteristics
and novel therapeutic strategies … A phase I study of the HDM2 antagonist SAR405838 …

… 3 study, trabectedin finally also received US Food and Drug Ad… BI 907828 is an oral MDM2-p53
antagonist that has shown … firstin-human phase 1 trial (NCT01636479) with SAR405838 …

… of the ongoing research of novel therapeutic strategies. … Trabectedin, a marine-derived
drug that binds to the minor … A first-in-human phase 1 trial (NCT01636479) of SAR405838, …

… In this study, we used the innovative MST to establish an … study provides novel insights
into the molecular mechanisms between the two proteins towards PPI-focused anticancer drug …